WO2022210228A1 - SYNTHASE D'α-ISOPROPYLMALATE MODIFIÉE - Google Patents

SYNTHASE D'α-ISOPROPYLMALATE MODIFIÉE Download PDF

Info

Publication number
WO2022210228A1
WO2022210228A1 PCT/JP2022/013788 JP2022013788W WO2022210228A1 WO 2022210228 A1 WO2022210228 A1 WO 2022210228A1 JP 2022013788 W JP2022013788 W JP 2022013788W WO 2022210228 A1 WO2022210228 A1 WO 2022210228A1
Authority
WO
WIPO (PCT)
Prior art keywords
residue
amino acid
modified
acid sequence
leucine
Prior art date
Application number
PCT/JP2022/013788
Other languages
English (en)
Japanese (ja)
Inventor
修平 中根
Original Assignee
Ｇｒｅｅｎ Ｅａｒｔｈ Ｉｎｓｔｉｔｕｔｅ株式会社
伊藤忠ケミカルフロンティア株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ｇｒｅｅｎ Ｅａｒｔｈ Ｉｎｓｔｉｔｕｔｅ株式会社, 伊藤忠ケミカルフロンティア株式会社 filed Critical Ｇｒｅｅｎ Ｅａｒｔｈ Ｉｎｓｔｉｔｕｔｅ株式会社
Priority to CN202280025165.7A priority Critical patent/CN117460829A/zh
Publication of WO2022210228A1 publication Critical patent/WO2022210228A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine

Definitions

  • the present invention provides a modified ⁇ -isopropylmalate synthase with reduced feedback inhibition by leucine, a polynucleotide encoding the modified ⁇ -isopropylmalate synthase, a genetically modified microorganism into which the polynucleotide has been introduced, and the gene
  • the present invention relates to a method for producing a desired substance using modified microorganisms.
  • the present application is based on Japanese Patent Application No. 2021 filed with the Japan Patent Office on March 29, 2021. The priority is claimed based on Japanese Patent Application No. 2021-054521, and the content of the above Japanese patent application is incorporated herein for all purposes. Additionally, the disclosure of each prior art document referred to in this application is also incorporated herein for all purposes.
  • L-leucine is a type of essential amino acid, an expensive amino acid that is widely used in pharmaceuticals, foods, feed additives, industrial chemicals, etc., and is mainly produced using microorganisms. Specifically, fermentative production of branched-chain amino acids including L-leucine is mainly carried out using Escherichia microorganisms or Corynebacterium microorganisms. It is known that 2-ketoisocaproic acid is biosynthesized as a precursor starting from pyruvic acid through various steps.
  • IPMS IP-isopropylmalate synthase
  • IPMS plays an important role in the L-leucine biosynthetic pathway
  • feedback inhibition often occurs, in which the enzymatic activity is inhibited by the final product L-leucine produced.
  • feedback inhibition has been a problem in the industrial production of L-leucine using microorganisms, and various techniques have been developed to solve this problem.
  • Patent Document 1 discloses a microorganism transformed with a DNA encoding ⁇ -isopropylmalate synthase that has L-leucine-producing ability and has been released from inhibition by L-leucine, and L - A method for the production of leucine is disclosed.
  • ⁇ -isopropylmalate synthase whose inhibition by L-leucine has been released is cloned from a mutant strain of E. coli having L-leucine-producing ability.
  • Patent Document 2 discloses a mutant IPMS in which the amino acid sequence of the wild-type IPMS encoded by the LeuA gene derived from Corynebacterium glutamicum is mutated to aspartic acid at the 553rd tyrosine residue. and a fermentation method for producing L-leucine or ketoisocaproate (KIC) using a microorganism introduced with the nucleotide, and the mutant IPMS is L-leucine, etc. It is mentioned that feedback inhibition of enzyme activity by is reduced.
  • KIC ketoisocaproate
  • a genetically modified strain was prepared by introducing a gene encoding the mutant IPMS (mutant leuA gene) into Corynebacterium glutamicum ATCC13032 strain, and the genetically modified strain , Using the wild-type ATCC13032 strain as a control, KIC and L-leucine production tests were conducted, and it was confirmed that the genetically modified strain was endowed with the ability to produce these substances compared to the wild-type ATCC13032 strain. ing.
  • Patent Document 3 also discloses a mutant IPMS having a predetermined amino acid substitution for an IPMS encoded by a LeuA gene derived from Corynebacterium glutamicum, and a recombinant Corynebacterium glutamicum introduced with a nucleic acid encoding the same.
  • a strain is disclosed, as well as a method for producing L-leucine using the recombinant strain.
  • the amino acid substitutions possessed by the above-mentioned mutant IPMS are the substitution of histidine for arginine at position 494 and the substitution of aspartic acid for glycine at position 497 in the amino acid sequence of IPMS used as a reference in the same document.
  • Patent Document 4 discloses a novel mutant polypeptide having IPMS activity, a polynucleotide encoding the same, a microorganism containing the polypeptide, and a method for producing L-leucine by culturing the microorganism.
  • the "novel mutant polypeptide having IPMS activity" more specifically refers to the 558th arginine in the wild-type IPMS amino acid sequence encoded by the Corynebacterium glutamicum-derived LeuA gene.
  • IPMS mutants that were actually produced and strains into which the IPMS mutants were introduced are IPMS mutants that possess amino acid substitutions of R558H, R558A, R558Q, G561D, G561R, and G561Y, respectively, and IPMS mutants having amino acid substitutions by a combination of R55H and G561D, and Corynebacterium glutamicum recombinant strains into which these mutants were respectively introduced, and these recombinant strains have L-leucine relative to the wild type. It has been confirmed that the productivity of
  • JP-A-2001-37494 Japanese Patent Publication No. 2015-514431 Chinese Patent Application Publication No. 104480058 Japanese Patent Publication No. 2020-503045
  • An object of the present invention is to provide novel IPMS mutants that can impart to various microorganisms the ability to produce derivatives containing L-leucine and its precursors.
  • Type ⁇ -isopropylmalate synthase (A) an amino acid sequence having at least two substitutions selected from the following (a) to (c) in the amino acid sequence shown in SEQ ID NO: 2; (B) an amino acid sequence having a sequence identity of 60% or more to the amino acid sequence shown in SEQ ID NO: 2 and containing at least two substitutions selected from (a) to (c) below; (C) the amino acid sequence shown in SEQ ID NO: 2, containing at least two substitutions selected from the following (a) to (c), and one or more at sites excluding the sites where the at least two substitutions are located amino acid sequences in which amino acids have been deleted, substituted, inserted or added; (a) replacement of the 530
  • [7] The modified ⁇ -isopropyl malate synthase of [6], wherein the at least one amino acid mutation includes all of the substitutions defined in (a') to (c') above.
  • [8] Any one of [1] to [7], including an amino acid sequence having at least two substitutions in the amino acid sequence of a wild-type 2-isopropylmalate synthase derived from a bacterium belonging to the genus Corynebacterium The modified ⁇ -isopropyl malate synthase described in .
  • Malate synthase (g) replacement of the 530th glycine residue or an amino acid residue corresponding to the glycine residue with an aspartic acid residue; (h) substitution of the 532nd glycine residue or an amino acid residue corresponding to the glycine residue with an aspartic acid residue; and (j) the 535th alanine residue or an amino acid corresponding to the alanine residue Substitution of residues for threonine, valine, glycine, leucine or isoleucine residues.
  • [16] A microorganism into which the polynucleotide of [15] has been introduced.
  • [17] A microorganism comprising the modified ⁇ -isopropylmalate synthase of any one of [1] to [14].
  • [18] The microorganism of [16] or [17], which is a coryneform bacterium.
  • [19] The microorganism of [18], which is Corynebacterium glutamicum.
  • the target substance is (2S)-2-isopropyl malate, 2-isopropyl malate, (2R,3S)-3-isopropyl malate, (2S)-2-isopropyl-3-oxosuccinate,
  • the method of [21] which is 4-methyl-2-oxopentanoate or L-leucine or a metabolite via these compounds on the biosynthetic pathway.
  • IPMS mutants that are highly resistant to feedback inhibition can be utilized and used to produce L-leucine and its derivatives, including its precursors, with high yield and productivity. can.
  • FIG. 2 is a diagram for use in explaining metabolic pathways that microorganisms may have in embodiments of the present invention.
  • An aspect of the present invention is a novel mutant polypeptide with IPMS activity. That is, according to this aspect, a modified ⁇ -isopropylmalate synthase with reduced L-leucine feedback inhibition is provided, as specified by the components shown in [1] or [6] above. More specifically, the novel mutant polypeptide comprises at least two of glycine, glycine, and alanine at positions 530, 532, and 535 from the N-terminus of a polypeptide consisting of the amino acid sequence of UniprotKB:P42455, or at least two of the amino acid residues corresponding to are replaced with different amino acid residues. Said mutant polypeptide is at least more resistant to feedback inhibition than the polypeptide having IPMS activity of UniprotKB:P42455.
  • UniprotKB The amino acid sequence of P42455 is the amino acid sequence of wild-type IPMS derived from Corynebacterium glutamicum ATCC13032/DSM20300/BCRC11384/JCM1318/LMG3730/NCIMB10025 strains.
  • sequence listing the nucleotide sequence containing the region (CDS) encoding the wild-type IPMS and the amino acid sequence of the wild-type IPMS in the genome sequence of Corynebacterium glutamicum ATCC13032 strain are listed in order of sequence numbers. 1,2.
  • “Feedback inhibition” in the present invention means that the final product of the metabolic system becomes an inhibitor and inhibits the reaction at the initial stage of the metabolic system.
  • it means that L-leucine or a derivative thereof inhibits the activity of IPMS that mediates the first step of its biosynthetic pathway. is widely known. Therefore, when simply referring to “feedback inhibition”, inhibitors against IPMS are not limited to L-leucine. Releasing feedback inhibition of IPMS can improve L-leucine productivity compared to others.
  • L-leucine feedback inhibition it means that IPMS is subject to feedback inhibition by L-leucine, and when saying "L-leucine feedback inhibition is reduced” or the like, it means that IPMS of interest is , means that at least the feedback inhibition by L-leucine is reduced or eliminated.
  • the modified ⁇ -isopropylmalate synthase described above has a property of reduced L-leucine feedback inhibition, and, although not necessarily essential, reduced feedback inhibition by L-leucine derivatives or other metabolites. It may have properties.
  • highly resistant to feedback inhibition means maintaining enzyme activity without being inhibited even in the presence of high concentrations of inhibitors. Resistance to feedback inhibition can be assessed by comparing IPMS activity in the presence of inhibitor to activity in the absence of inhibitor.
  • the IPMS in the present invention may be derived from any organism as long as it is a modified enzyme having the conversion activity and reduced feedback inhibition, but is preferably an enzyme derived from a coryneform bacterium. More preferably, it may be an IPMS derived from Corynebacterium glutamicum. It is not limited.
  • said IPMS has at least 80%, 84%, 90%, 95%, 96%, 97%, 98% or 99% sequence homology or sequence identity with the amino acid sequence of UniprotKB:P42455 (SEQ ID NO: 2) may include a polypeptide having For example, an amino acid sequence having such sequence homology or sequence identity and showing an effect corresponding to IPMS may have an amino acid sequence in which a part of the sequence is deleted, modified, substituted or added. Needless to say, it is included in the present invention.
  • the homologous amino acid residue to be mutated can be estimated by aligning with UniprotKB:P42455.
  • Common programs can be used for alignment, such as Clustal and BLAST. Alignments may be conformational superpositions, for which reason they can be evaluated, for example, by utilizing molecular graphics tools such as PyMOL.
  • coryneform bacterium refers to a group of microorganisms defined in Burgeys Manual of Determinative Bacteriology (Vol. 8, p.599, 1974). More specifically, coryneform bacteria include Corynebacterium spp., Brevibacterium spp., Arthrobacter spp., Mycobacterium spp., Micrococcus ) genus, Microbacterium genus, and the like. For more details, reference can be made to the definitions described in WO2019156152A1.
  • “Mutation”, “mutant” or “mutant” in the present invention refers to genes, polypeptides, enzymes, or microorganisms possessing them, in which the base sequence of a gene is altered and the amino acid sequence is accordingly altered.
  • IPMS mutant or mutant IPMS means a mutant in which the amino acid sequence of IPMS is changed by one or more amino acids compared to the wild type, and the activity and the degree of feedback inhibition to L-leucine and its derivatives are changed. do.
  • mutant polypeptides having IPMS activity of the present invention are amino acid residues 530, 532, and 535 from the N-terminus of a polypeptide consisting of the amino acid sequence of UniprotKB: P42455, glycine, glycine, and alanine, or at least two of the amino acid residues corresponding to those amino acids may be substituted with different amino acid residues.
  • the another amino acid residue refers to one amino acid residue selected from 19 types of 20 standard amino acids excluding the amino acid residue before mutation in wild-type IPMS.
  • the mutant polypeptide includes the amino acid sequence shown in SEQ ID NO: 2 (Table 1) and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, Polypeptides with 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology or identity may be included. .
  • SEQ ID NO: 2 Table 1
  • polypeptides with 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology or identity may be included.
  • it is an amino acid sequence that has such sequence homology or sequence identity and shows an effect corresponding to IPMS, in addition to mutations at positions 530, 532, and 535, a part of the sequence is deleted or modified.
  • enzyme variants having substituted or added amino acid sequences are also included in the present invention.
  • the present invention includes those calculated in consideration of the number of amino acids when some amino acids are added
  • “one or more” (“one or The range of “plurality”) is not particularly limited, but in certain embodiments, for example, 1 to 400, 1 to 300, 1 to 200, 1 to 100, 1 to 50, 1 30 from .
  • the range of "one or more" (“one or more") is at least 2 or more, preferably 2 to 20, more preferably 2 to 10, even more preferably 2 to 5 particularly preferably 2 to 4, 2 to 3, for example 2.
  • the “corresponding wild-type 2-isopropylmalate synthase ( ⁇ -isopropylmalate synthase)” may be interpreted literally, and the present invention
  • wild-type 2-isopropyl malate synthase ( ⁇ -isopropyl malate synthase) that serves as a reference for reducing L-leucine feedback inhibition.
  • the modified ⁇ -isopropylmalate synthase may reduce the degree of L-leucine feedback inhibition compared to the reference wild-type 2-isopropylmalate synthase ( ⁇ -isopropylmalate synthase) at least 1 have one amino acid mutation, and the at least one amino acid mutation contains at least two of the amino acid substitutions defined in (a'), (b') and (c') above Enough.
  • the meanings of the “corresponding amino acid residues” described in (a′), (b′) and (c′) are SEQ ID NO: 2, the substitution site is specified in the IPMS amino acid sequence to be mutated. That is, the "corresponding amino acid residues" in the above (a'), (b') and (c') are specifically ClustalW and ClustalX (Bioinformatics, Vol. 23, Issue 21, 2008 11 Month, pp. 2947-2948; Bioinformatics, Volume 23, Issue 21, 1, November 2007, pp 2947-2948), the amino acid sequence of IPMS to be mutagenized for the amino acid sequence shown in SEQ ID NO: 2. Aligned one-to-one with each amino acid residue shown in (a'), (b') and (c') above when one-to-one alignment (pairwise alignment) is performed based on identity say amino acids.
  • the modified ⁇ -isopropyl malate synthase of the present invention is ⁇ G530F/G532D/A535T ⁇ G530N/G532D/A535T ⁇ G530C/G532D/A535T ⁇ G530P/G532D/A535T ⁇ G530R/G532D/A535T ⁇ G530L/G532D/A535T ⁇ G530I/G532D/A535T ⁇ G530T/G532D/A535T ⁇ G530H /G532D/A535T ⁇ G530D/G532E/A535T ⁇ G530D/G532K/A535T ⁇ G530D/G532A/A535T ⁇ G530D/G532V/A535T ⁇ G530D/G532F/A535T ⁇ G530D/G532N/A535T ⁇ G530D/G532C/A535T ⁇ G530P/G53
  • the amino acid sequence that the modified ⁇ -isopropylmalate synthase of the present invention can have is obtained by BLAST known to those skilled in the art for the amino acid sequence shown in SEQ ID NO: 2 (wild-type IPMS of Corynebacterium glutamicum ATCC13032 strain). Analysis can be performed and design can be made based on the amino acid sequences of various IPMS homologues retrieved thereby.
  • BLAST analysis of the amino acid sequence shown in SEQ ID NO: 2 revealed, for example, Corynebacterium deserti-derived IPMS (Accession No. WP_053543926.1, sequence identity 94.64%), Corynebacterium efficiens-derived IPMS (Accession No.
  • amino acid sequences that the modified ⁇ -isopropylmalate synthase according to the present invention may have can be designed. Please note that these Accession No.
  • the amino acid sequences identified by are incorporated herein by reference.
  • the above (a'), (b') and (c'), or the above (d), (e) and (f), or the above (g), (h) and ( A mutant polypeptide having an amino acid sequence obtained by making at least two of each of the amino acid substitutions shown in j) is specified herein as an embodiment of the modified ⁇ -isopropylmalate synthase according to the present invention. It is what is done.
  • the modified ⁇ -isopropylmalate synthase of the present invention is eukaryotic, prokaryotic, fungal, bacterial, archaeal, coryneform, corynebacterium (e.g., Corynebacterium glutamicum, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium halotolerans, Corynebacterium ammoniagenes, Corynebacterium maris, Corynebacterium hadale) in the amino acid sequences of the wild-type ⁇ -(c′), Alternatively, it has an amino acid sequence obtained by performing at least two of the amino acid substitutions shown in (d), (e) and (f) above, or (g), (h) and (j) above.
  • corynebacterium e.g., Corynebacterium glutamicum, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium haloto
  • polynucleotide encoding said mutant polypeptide.
  • the polynucleotide may have any sequence as long as it contains a nucleotide sequence that encodes the mutant polypeptide or modified ⁇ -isopropylmalate synthase of the present invention.
  • the polynucleotide of the wild-type leuA gene before mutagenesis may be a sequence amplified by PCR from genomic DNA prepared from an organism having the leuA gene, or a nucleotide sequence designed based on known genetic information is artificially synthesized. good too. Any combination of codons may be used as long as they encode the same polypeptide, and the codon usage frequency, secondary structure, etc. may be taken into account in the design.
  • the method of introducing mutations into the wild-type polynucleotide may be in vitro or in vivo.
  • Methods for introducing mutations in vitro include, but are not limited to, PCR-based methods using mutated primers, and random mutation-introducing methods by performing PCR under error-prone conditions.
  • Methods for introducing mutations in vivo include, but are not limited to, a method of spontaneously mutating by repeating passages in culture, and a method of treatment with a mutagen such as ultraviolet light or an alkylating agent.
  • the microorganisms of the present invention are capable of producing derivatives containing L-leucine and its precursors. Additionally, in some embodiments, the microorganisms of the present invention are microorganisms, including eukaryotic microorganisms such as, for example, fungi, prokaryotes, bacteria, archaea, corynebacterium, coryneform bacteria.
  • L-leucine corresponds to all intermediates in the leucine biosynthetic pathway after 2-ketoisovaleric acid such as isopropylmalic acid and 2-ketoisocaproic acid.
  • FIG. Contains various metabolites that make up the L-leucine biosynthetic pathway shown in .
  • derivatives of L-leucine include all substances that can be biosynthesized from L-leucine and its precursors. These include, but are not limited to, 3-hydroxyisovaleric acid derived from 2-ketoisocaproic acid, 3-methylbutanol, isoamylacetic acid, and the like.
  • microorganisms in the present invention include those artificially produced by transformation and naturally occurring ones.
  • the microorganism may be a microorganism transformed with a vector containing a polynucleotide encoding the mutant polypeptide (modified ⁇ -isopropylmalate synthase).
  • the microorganisms include microorganisms that express the mutant polypeptide (modified ⁇ -isopropylmalate synthase) by various known methods.
  • the polynucleotide encoding the mutant polypeptide (modified ⁇ -isopropylmalate synthase) may be introduced into the microorganism in a form capable of being expressed in host cells.
  • a polynucleotide encoding the mutant polypeptide (modified ⁇ -isopropylmalate synthase) is converted into a mutant polypeptide (modified ⁇ -isopropylmalate synthase) in host cells. Synthase) may be introduced in a form that does not express.
  • the transformed gene polynucleotide encoding the mutant polypeptide
  • the mutant polypeptide modified ⁇ -isopropyl malate synthase
  • the polynucleotide encoding the mutant polypeptide may be in any form. may have the form of DNA or RNA.
  • the microorganism according to the present invention expresses the mutant polypeptide (modified ⁇ -isopropylmalate synthase) and, in addition, 3-methyl-2-oxobutanoate , (2S)-2-isopropyl maleate, 2-isopropyl maleate, (2R,3S)-3-isopropyl maleate, (2S)-2-isopropyl-3-oxosuccinate, 4-methyl-2-oxo It has a biosynthetic pathway that biosynthesizes pentanoate and L-leucine in this order.
  • the microorganism according to the present invention expresses the mutant polypeptide (modified ⁇ -isopropylmalate synthase), and at least one of these compounds on the biosynthetic pathway It has one or more biosynthetic pathways that biosynthesize metabolites derived from one.
  • the microorganism according to the present invention may have reduced or inactivated wild-type ⁇ -isopropylmalate synthase activity.
  • the microorganism when the wild-type ⁇ -isopropylmalate synthase activity is reduced or inactivated, the microorganism has an adverse effect on the production of the target substance due to the L-leucine feedback inhibition exhibited by the wild-type enzyme.
  • Expression of the modified ⁇ -isopropylmalate synthase in which the feedback inhibition is reduced while being eliminated allows the metabolic reaction to the target substance to proceed efficiently.
  • the reduction or inactivation of wild-type ⁇ -isopropylmalate synthase activity in microorganisms is performed by leuA present on the genome or its homolog gene (wild-type ⁇ -isopropylmalate synthase-encoding gene) or regulation of gene expression thereof. It can be realized by a technique such as disruption of the region (e.g. promoter region).
  • the method for producing a target substance comprises (I) culturing or reacting coryneform bacteria capable of producing L-leucine among the microorganisms according to the present invention in a medium to produce L-leucine or metabolize L-leucine. (b) recovering the L-leucine or metabolite produced in step (II) from the microorganism or culture medium; .
  • “Culturing” generally means growing the microorganism under suitably controlled environmental conditions, and “cultivating or reacting” in the present invention has such a general meaning. but not limited to the culture of, for example, culture or reaction modes that can realize the production of the target substance by allowing at least a part of the metabolism of the microorganism to function without substantial growth of the microorganism. do.
  • the culturing or reaction process in the present invention can be carried out by employing suitable media/reaction media and culturing conditions known in the art. Such a culture/reaction process can be easily adjusted and used according to the strain selected by those skilled in the art.
  • the culture or reaction, ie step (I) may be, but is not limited to, batch, continuous and fed-batch culture.
  • step (I) the culture or reaction conditions are not limited as long as the microorganism according to the present invention can produce the target substance.
  • step (I) is carried out under microaerobic or aerobic conditions.
  • step (I) is performed at a concentration of dissolved oxygen (DO) of said predetermined culture medium or reaction medium from about 0 to about 60 ppm, preferably from about 0 ppm to about 40 ppm, such as from about 0 ppm to about 8.0 ppm. Carry out step (I) so that the range is 0 ppm.
  • DO dissolved oxygen
  • step (I) is carried out such that the dissolved oxygen concentration (DO) ranges from about 0 ppm to about 2 ppm, preferably from about 0 to about 1 ppm, more preferably from 0 to 0.5 ppm.
  • the ORP oxidation-reduction potential
  • the ORP is about -500 mV to about 700 mV, about -500 mV to about 550 mV, about -400 mV to about 500 mV, about -400 mV to about 400 mV, about Perform step (I) to a range of 350 mV, from about -300 mV to about 300 mV, from about -250 mV to about 200 mV, or from about -250 mV to about 100 mV.
  • step (I) when using microorganisms that can be cultured at high density, such as coryneform bacteria, if step (I) is performed under microaerobic or aerobic conditions with air aeration and agitation, , the DO and ORP of the medium or reaction medium decrease with the growth of the microorganism, and after sufficient growth, the DO value becomes almost zero and the ORP value decreases to the range of about -300 mV to about -200 mV. .
  • the DO may not be zero depending on the type and properties of the microorganisms used and various conditions such as stirring throughout the period, and the present invention is not limited by the above numerical range.
  • the target substance is (2S)-2-isopropylmalate, 2-isopropylmalate, (2R,3S)-3-isopropylmalate, (2S)-2-isopropyl-3-oxo Succinate, 4-methyl-2-oxopentanoate or L-leucine, or metabolites via these compounds on the biosynthetic pathway.
  • the compounds from (2S)-2-isopropylmalate to L-leucine are metabolites in the L-leucine biosynthetic pathway that microorganisms may have.
  • FIG. 1 the compounds from (2S)-2-isopropylmalate to L-leucine are metabolites in the L-leucine biosynthetic pathway that microorganisms may have.
  • the method for recovering the target substance produced in step (I) is not particularly limited. , recovering the target substance (e.g. L-leucine or its precursor, derivative or derivative) from the microorganism or medium or reaction medium using a suitable method known in the art, depending on the culture/reaction method be able to. For example, centrifugation, filtration, anion exchange chromatography, crystallization, HPLC, etc., can be used to recover the target substance from the microorganism or culture medium or reaction medium using suitable methods known in the art.
  • the recovery step according to (II) includes a step of recovering a fraction containing the target substance or a crude product. may further include a step of purifying the
  • IPMS gene amino acid sequence of coryneform bacterium (UniprotKB: P42455) was obtained, and restriction enzymes NdeI and BamHI recognition sequences were added to the 5′ and 3′ ends by artificial gene synthesis. synthesized DNA. A DNA fragment obtained by cleaving this DNA with NdeI and BamHI was mixed with a fragment obtained by cleaving the expression vector pGE409 (WO2020090016A1) with the same restriction enzymes and ligated with T4 DNA ligase (NEB). The resulting plasmid was named pGE1835.
  • Mutagenesis 2 (permissive evaluation of each residue based on triple mutants) Mutagenesis was performed using various predetermined primer pairs and pGE1881 as a template by the same method as described in WO2019156152A1.
  • Plasmids for chromosome gene recombination were obtained by performing PCR using the genomic DNA of Corynebacterium glutamicum ATCC13032 as a template, using various predetermined primer pairs, and cloning the DNA fragment of pGE209 (WO2019156152A1) cut with KpnI and BamHI. Plasmid vector pGE1781 was obtained by circular ligation using Kit.
  • pGE1781 was introduced into Corynebacterium glutamicum ATCC13032 strain by electroporation, and ⁇ leuA strain was produced by the markerless genetic recombination method described in WO2019156152A1.
  • IPMS Mutant Overexpressing Strain The ⁇ leuA strain was electroporated with each expression plasmid shown in Tables 3 and 4 and selected with kanamycin to obtain a mutant IPMS overexpressing strain.
  • the pellet was suspended in a disruption buffer (50 mM Tris (7.5), 100 mM KCl, 1 mM EDTA), and cells were disrupted with a bead shocker according to the method described in (WO2020090016A1).
  • the protein concentration of the cell lysate was quantified according to the Bradford method.
  • the enzymatic activity of isopropylmalate synthase in cell lysate was 100 mM Tris-HCl (pH 7.5), 2 mM 4-PDS (4,4'-Dithiodipyridine), 2 mM Acetyl-CoA, 2 mM 3 -Methyl-2-oxobutanoic acid was mixed with the cell lysate, and the change in absorbance at 324 nm due to the reaction of liberated CoA with 4-PDS to produce 4-thiopyridine was measured. For measurements of feedback inhibition by L-leucine, 10 mM L-leucine was added to the reaction.
  • Glucose 40g ( NH4) 2SO4 20g, urea 5g, KH2PO4 1g, K2HPO4 1g , MgSO4.7H2O 0.25g , MOPS 42g , CaCl2 10mg , FeSO4.7H2O 10 mg, MnSO4.H2O 10 mg, ZnSO4.7H2O 1 mg, CuSO4 0.2 mg, NiCl2.6H2O 0.02 mg, biotin 0.2 mg, thiamine hydrochloride 0.2 mg, PCA 30 mg/L , pH 7.4
  • G530D, G530E, G530K, G530A, G530V, G530N, G530C, G530P, G530R, G530L, G530I, G530T, G530H, G532D, G532A, G532V, G532P, G532L, G532T, G532T, G532T, G532T, G530D, G530E, G530K, G530A, G530V, G530N, G530C, G530P, G530R, G530L, G530I, G530T, G530H, G532D, G532A, G532V, G532P, G532L, G532T, G532T, G5322 , A535S, A535V, A535K, A535D, A535F, A535G, A535L, A535I, and A535H are expected to improve the performance of IPMS, which is effective in increasing L-leucine
  • the present invention has high industrial applicability in the field of industrial production of various chemical substances.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau mutant IPMS pouvant conférer, à divers micro-organismes, la capacité de produire un dérivé comprenant de la L-leucine ou un de ses précurseurs. Le mutant IPMS contient au moins deux substitutions d'acides aminés choisies parmi les (a') à (c') suivants sur la base de la séquence d'acides aminés représentée dans SEQ ID NO : 2, à savoir : (a') substitution du résidu d'acide aminé correspondant au résidu glycine en position 530 par un résidu d'acide aminé autre qu'un résidu glycine ; (b') substitution du résidu d'acide aminé correspondant au résidu glycine en position 532 par un résidu d'acide aminé autre qu'un résidu glycine ; et (c') substitution du résidu d'acide aminé correspondant au résidu alanine en position 535 par un résidu d'acide aminé autre qu'un résidu alanine.
PCT/JP2022/013788 2021-03-29 2022-03-24 SYNTHASE D'α-ISOPROPYLMALATE MODIFIÉE WO2022210228A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280025165.7A CN117460829A (zh) 2021-03-29 2022-03-24 修饰型α-异丙基苹果酸合酶

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-054521 2021-03-29
JP2021054521 2021-03-29

Publications (1)

Publication Number Publication Date
WO2022210228A1 true WO2022210228A1 (fr) 2022-10-06

Family

ID=83458736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/013788 WO2022210228A1 (fr) 2021-03-29 2022-03-24 SYNTHASE D'α-ISOPROPYLMALATE MODIFIÉE

Country Status (2)

Country Link
CN (1) CN117460829A (fr)
WO (1) WO2022210228A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001037494A (ja) * 1999-07-09 2001-02-13 Ajinomoto Co Inc 変異型イソプロピルマレートシンターゼをコードするｄｎａ、ｌ−ロイシン生産性微生物、および、ｌ−ロイシンの製造法
JP2015514431A (ja) * 2012-04-27 2015-05-21 エボニック インダストリーズ アクチエンゲゼルシャフトＥｖｏｎｉｋ Ｉｎｄｕｓｔｒｉｅｓ ＡＧ フィードバック耐性アルファ−イソプロピルリンゴ酸合成酵素
JP2015529459A (ja) * 2012-08-22 2015-10-08 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング フィードバック阻害が低下したまたはオフとなった酵素をコードする遺伝子を含有するベクターの製造方法、ならびにアミノ酸およびヌクレオチドを生産するための、その使用
CN109456987A (zh) * 2018-10-26 2019-03-12 天津科技大学 高产l-亮氨酸的相关基因及工程菌构建方法与应用
JP2020503045A (ja) * 2016-12-28 2020-01-30 シージェイ チェイルジェダン コーポレーション 新規なイソプロピルリンゴ酸シンターゼ変異体及びそれを用いたｌ−ロイシンの生産方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001037494A (ja) * 1999-07-09 2001-02-13 Ajinomoto Co Inc 変異型イソプロピルマレートシンターゼをコードするｄｎａ、ｌ−ロイシン生産性微生物、および、ｌ−ロイシンの製造法
JP2015514431A (ja) * 2012-04-27 2015-05-21 エボニック インダストリーズ アクチエンゲゼルシャフトＥｖｏｎｉｋ Ｉｎｄｕｓｔｒｉｅｓ ＡＧ フィードバック耐性アルファ−イソプロピルリンゴ酸合成酵素
JP2015529459A (ja) * 2012-08-22 2015-10-08 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング フィードバック阻害が低下したまたはオフとなった酵素をコードする遺伝子を含有するベクターの製造方法、ならびにアミノ酸およびヌクレオチドを生産するための、その使用
JP2020503045A (ja) * 2016-12-28 2020-01-30 シージェイ チェイルジェダン コーポレーション 新規なイソプロピルリンゴ酸シンターゼ変異体及びそれを用いたｌ−ロイシンの生産方法
CN109456987A (zh) * 2018-10-26 2019-03-12 天津科技大学 高产l-亮氨酸的相关基因及工程菌构建方法与应用

Also Published As

Publication number Publication date
CN117460829A (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
CN108884449B (zh) 新型异丙基苹果酸合酶变异体及使用其生产l-亮氨酸的方法
EP3597738B1 (fr) Homosérine déshydrogénase modifiée et procédé de production d'homosérine ou d'acide l-aminé dérivé d'homosérine l'utilisant
KR20130072183A (ko) Ｌ-라이신 생산능을 갖는 미생물을 이용하여 ｌ-라이신을 생산하는 방법
EP3690036A1 (fr) Homosérine déshydrogénase modifiée et procédé de production d'acide l-aminé d'homosérine ou d'homosérine l'utilisant
JP2023503077A (ja) 新規な分枝鎖アミノ酸アミノトランスフェラーゼ変異体及びそれを用いたロイシン生産方法
CN113249347A (zh) 丙酮酸脱氢酶的突变体及其用于生产l-氨基酸的方法
KR101359844B1 (ko) 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법
DK2430152T3 (en) A microorganism with increased L-lysine productivity and method for producing L-lysine using the same
CN110997899B (zh) 嗜热赖氨酸脱羧酶的异源表达及其用途
CN109790557B (zh) 控制生物膜分散以产生氨基酸或氨基酸衍生产物
CN111406104B (zh) 减少为了生产氨基酸或氨基酸衍生产物的亚胺/烯胺的积累
WO2022210228A1 (fr) SYNTHASE D'α-ISOPROPYLMALATE MODIFIÉE
EP4230723A1 (fr) Polypeptide à activité d'aspartate kinase et son utilisation dans la production d'acides aminés
CN113278620B (zh) 一种突变的高渗诱导型启动子PproP及其应用
KR102589135B1 (ko) 3-메틸-2-옥소뷰타노에이트 하이드록시 메틸트랜스퍼라아제의 활성이 강화된 미생물, 및 이의 용도
JP7214952B2 (ja) オルニチン脱炭酸酵素変異型及びそれを用いたプトレシンの生産方法
KR102233376B1 (ko) 메조 디아미노피멜레이트 디하이드로게네이즈 변이형 폴리펩타이드 및 이를 이용한 l-쓰레오닌 생산방법
CN116888141A (zh) Glxr蛋白变体或使用其生产苏氨酸的方法
CN115003807A (zh) 新半胱氨酸亚磺酸脱硫酶变体及使用其生产l-缬氨酸的方法
JP2018517411A (ja) Ｏ−アセチルホモセリンを生産する微生物及びそれを用いてｏ−アセチルホモセリンを生産する方法
EP2397545B1 (fr) Procédé de production d'un acide aminé
KR102377745B1 (ko) 신규 프로모터 및 이의 용도
CN115052976B (zh) 新型乙酰羟酸合酶变体和包括其的微生物
WO2008026698A1 (fr) Procédé de production d'acide l-glutamique
EP4253532A1 (fr) Variant d'isopropylmalate synthase et procédé de production de l-leucine à l'aide de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22780442

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280025165.7

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22780442

Country of ref document: EP

Kind code of ref document: A1